Early Warning System

EIB-20220380 AFFIBODY (INVESTEU VD)



Early Warning System AFFIBODY (INVESTEU VD)

Quick Facts

Countries	Sweden
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2022-12-22
Borrower	Affibody Medical AB
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Loan Amount (USD)	\$ 21.20 million
Project Cost (USD)	\$ 60.43 million

Project Description

As stated by the EIB, the project consists of the development and modernisation of next generation multi-specifics biologics based products, matching the unmet needs in the immunology and oncology field.

Early Warning System Project Analysis

People Affected By This Project

Investment Description


• European Investment Bank (EIB)

Private Actor Relationship

Private Actors Description

From the company's website:

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platform.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Affibody Medical AB	Client	Education and Health

Contact Information

No project contacts available at the time of disclosure.

Client - Affibody Medical AB:

Address: Affibody AB, Scheeles väg 2, SE-171 65 Solna

Email: reception@affibody.com Phone: +46 (0)8 59 88 38 00 Website: www.affibody.se

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints mechanism policy en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Bank Documents

• Environmental and Social Data Sheet

Media

• Sweden: EIB lends €20 million to biotech company for development of biopharmaceuticals to treat canc

Other Related Projects

• EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL